Overlooked molecule might be key to how well cancer-fighting CAR-T cells work
A mostly overlooked component of CAR-T cells has a surprisingly strong effect on the cancer-fighting cells’ behavior, including in ways that might affect their safety and efficacy.
A mostly overlooked component of CAR-T cells has a surprisingly strong effect on the cancer-fighting cells’ behavior, scientists reported on Tuesday, including in ways that might affect their safety and efficacy.
The component is called the co-stimulatory domain, and the two CAR-T therapies approved last year to treat forms of leukemia and lymphoma — Yescarta and Kymriah — use different ones.
Although the authors of the new , in Science Signaling, are careful not to say one co-stimulatory domain is better than the other, their analyses of CAR-Ts in test tubes
